Platform 03 · Health

A natural, non-antibiotic alternative to antibiotics

Antimicrobial resistance is not bad luck. It is the predictable output of a mechanism: antibiotics apply selective pressure, and bacteria adapt. This platform works by a different mechanism entirely, so it never applies that pressure.

Dental · clinically validated JP 7768769 MX 433331 USPTO pending
OUTER MEMBRANE CATIONS REMOVED PEPTIDOGLYCAN STRUCTURAL FAILURE

What is proven, and what is not

Three statements that are not the same statement

Clinical validation, applied technology readiness and regulatory authorization get used interchangeably across this industry. They are different things, and conflating them is how credibility is lost. Here is where each application actually stands.

DentalClinically validated in humans, under the corresponding bioethical approvals
MedicalDeveloped and investigated. Not represented as clinically validated
VeterinaryDeveloped and investigated. Not represented as clinically validated
RespiratoryLargest opportunity, least developed. Clinical partners sought
→

“Ready for deployment” means the technology is developed far enough to transfer to an industrial partner. It does not mean a finished product carries regulatory authorization. Aybar Ecotechnologies develops the technology and its applications; it is not the manufacturer of the finished goods. Finding partners who can take these through manufacturing, registration and commercialization is the purpose of this page.

The mechanism

Why resistance does not develop

Antibiotics interfere with a metabolic pathway. Any mutation that routes around that pathway survives and propagates, which is what makes resistance inevitable rather than unlucky.

This formulation does not compete with bacterial metabolism at all. It dismantles the envelope mechanically.

  1. The chelating agent strips the divalent cations holding the gram-negative outer membrane together.
  2. That exposes the peptidoglycan layer normally shielded from enzymatic attack.
  3. Lysozyme cleaves the peptidoglycan directly, and the cell fails structurally.
  4. The pH-stabilizing salt keeps the system active under physiological conditions.
01 INTACT 02 CHELATION 03 EXPOSED 04 LYSIS
Non-antibiotic bactericidal mechanism · schematic

Broad-spectrum, including gram-negative

The granted claims cover a composition with bactericidal activity against both gram-positive and gram-negative bacteria. That second one is the boundary most enzyme-based approaches never crossed: lysozyme alone cannot reach the peptidoglycan of a gram-negative cell, because the outer membrane is in the way. The chelation system is what removes that obstacle.

Clinical evidence · dental indication

Measured against the reference antiseptic, in humans

This is not in vitro work, laboratory experimentation, or a theoretical result described in a patent. A comparative clinical study of 70 human subjects, conducted under the corresponding bioethical approvals, set the experimental formulation against chlorhexidine 0.12%, the reference oral antiseptic.

1.51.0 0.50 DAY 0DAY 7DAY 14 GINGIVAL INDEX CHLORHEXIDINE 0.12% EXPERIMENTAL FORMULATION
Gingival index over 14 days · schematic of the reported outcome
0Gingival index at end of study. Chlorhexidine stayed above 0.5 in almost half of subjects
14Days to zero recorded bleeding sites
75%Of treated cases with gingival inflammation minimized
0Adverse events attributable to the formulation
Unpleasant taste was reported by 14% in the extraction group, against 88% for chlorhexidine. Taste perception was unaltered in 0% of experimental cases, against 50% in extraction and 71% in implants. Comparative clinical study · n=70 · patent MX 433331

Favorable results were also reported for pain, inflammation and bleeding control following extractions and implants. Tolerability matters more than it sounds: an antiseptic that patients dislike is an antiseptic patients stop using.

Applications

One platform, four routes to market

Dental and oral care

Chewable tablets, bactericidal gel and irrigation solutions, for antibacterial oral hygiene, gingivitis and periodontal disease, asepsis during dental surgery, and post-extraction and post-implant recovery. This is the validated indication.

Medical and healthcare

Post-surgical asepsis and wound healing, where resistance-free antibacterial action is valuable and the safety profile observed in the dental study is informative, though not a substitute for clinical evaluation in those indications.

Veterinary

Livestock and poultry health, where antibiotic dependency is under regulatory pressure worldwide and a non-antibiotic route has a clear commercial path.

Respiratory and force health protection

Respiratory illness is a persistent operational risk in military settings: close-quarters living, high operational stress, and exposure to airborne hazards including dust, burn pits and industrial emissions. A safe, non-antibiotic platform could contribute to force readiness and lower antibiotic dependency. Establishing that requires the clinical work we are seeking partners to run.

PLATFORM DENTAL VALIDATED MEDICAL IN DEV. VET IN DEV. RESPIR. SEEKING PHASE 1 MARKET ENTRY ORAL CHEWABLE · DSHEA SUPPLEMENT FAST-ENTRY VALIDATION, NOT THE END OBJECTIVE
Application map and current evidence level

Intellectual property

One family, filed May 2020

Broad-spectrum antibacterial formulations comprising lysozyme and methods of using the same. Inventor of record: Diógenes Aybar-Batista. Patentee: Aybar Ecotechnologies Corp.

  • 28 May 2019United States provisional 62/853,215 establishes priority.
  • 28 May 2020International filing date. Every member of the family flows from here.
  • 17 November 2022Published in the United States as US 2022/0362354 A1.
  • 4 November 2025Granted in Japan, patent JP 7768769 (application 2021-571513).
  • 23 March 2026Granted in Mexico by IMPI, patent 433331 (solicitud MX/a/2021/014634).
  • 28 May 2040Mexican term expires. Twenty years from the international filing date.
Patent family
JurisdictionNumberStatus
Japan (JPO)JP 7768769Granted
Mexico (IMPI)433331Granted
United StatesUS 2022/0362354 A1Pending

International classification (Mexico): A61K 38/47; A61K 9/00; A61K 47/12; A61K 47/18; A61P 31/00.

A regulatory authorization is not a universal approval of a technology. It attaches to a specific product, its classification, and the jurisdiction where it is made or sold. Any product derived from this platform follows the corresponding pathway in each market a partner chooses to enter.

Partnership

What we are looking for

Partners with the capacity to develop, register, manufacture and commercialize products derived from this technology, through licensing, co-development or other commercial arrangements. Separately, clinical partners for the respiratory work.

Formulation details, know-how and the full technical dossier are shared under a non-disclosure agreement.

Licensing & partnerships

Work with us on what comes next

Aybar Ecotechnologies works through licensing, joint ventures, and equity structures. Request the investor brief for a specific platform, or schedule a technical demonstration with our research team.